The Supreme Court agreed to wade into a high-stakes clash between federal pesticide regulation and state consumer-protection law, accepting a case that could reshape how far states can go in requiring cancer warnings on products the federal government has declined to label as dangerous.
The dispute centers on Roundup, the widely used weedkiller made by Bayer (formerly Monsanto), and whether California's Proposition 65 can force a cancer warning onto a product whose federal label carries no such caution. The justices will hear arguments in Bayer v. Monsanto during their next term, as SCOTUSblog first reported.
At the core of the case sits a deceptively simple question: Does the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA, preempt California from slapping its own cancer warning on a pesticide label that the Environmental Protection Agency has already approved without one?
The tension traces back to a split between federal and state scientific conclusions about glyphosate, the active ingredient in Roundup. The EPA has repeatedly found that glyphosate is "not likely to be carcinogenic to humans." The agency reaffirmed that position in its 2020 interim registration review.
California sees it differently. The state's Office of Environmental Health Hazard Assessment added glyphosate to its Proposition 65 list in 2017, relying on a 2015 classification by the International Agency for Research on Cancer, a branch of the World Health Organization. IARC categorized glyphosate as "probably carcinogenic to humans," a Group 2A designation.
That IARC finding has drawn sharp criticism from other regulatory bodies. The European Food Safety Authority, Health Canada, and the Australian Pesticides and Veterinary Medicines Authority have all concluded that glyphosate does not pose a carcinogenic risk to humans at typical exposure levels. The EPA itself rejected the IARC classification when it completed its own review.
Bayer argues that FIFRA's labeling provisions occupy the field and that a state cannot force a company to add a warning the EPA never required and, in fact, effectively rejected. The company contends that allowing California to mandate a Prop 65 cancer warning would create a direct conflict with the federal label, which was approved without any cancer disclosure.
FIFRA contains an express preemption clause. Section 136v(b) bars states from imposing labeling requirements that differ from, or add to, federal labeling mandates. But the statute also preserves state authority to regulate the sale and use of pesticides under Section 136v(a).
The Ninth Circuit ruled that California's Prop 65 warning requirement was not preempted. The appeals court reasoned that the state was not dictating the content of the pesticide label itself but instead imposing a general consumer-disclosure obligation that applies across product categories. Under that reading, Prop 65 operates as a marketplace regulation, not a labeling directive in conflict with FIFRA.
Bayer challenged that distinction as formalistic. In its cert petition, the company argued that a state law compelling a cancer warning on a product's point-of-sale materials functions as a labeling requirement regardless of how the state characterizes it. The practical effect, Bayer maintained, is the same: consumers receive a cancer message that contradicts the EPA's scientific judgment.
The Supreme Court's decision to grant review signals that at least four justices found the question worth resolving. The case arrives at a Court that has shown growing interest in the boundaries of federal preemption and the limits of state regulatory power, a theme visible across recent disputes involving environmental and energy regulation.
The financial stakes are enormous. Bayer inherited a tidal wave of litigation when it acquired Monsanto in 2018 for $63 billion. Since then, the company has faced more than 100,000 lawsuits from plaintiffs alleging that Roundup caused their non-Hodgkin lymphoma. Bayer has already paid more than $10 billion in settlements.
Many of those lawsuits leaned heavily on the IARC classification and on state-law failure-to-warn theories. A Supreme Court ruling that FIFRA preempts state cancer-warning mandates could cut the legs out from under a significant portion of the remaining claims. Conversely, a ruling that upholds California's authority would reinforce the legal foundation for future state-level labeling actions against federally regulated products.
The case also carries implications well beyond Roundup. Agricultural trade groups, chemical manufacturers, and business associations filed amicus briefs urging the Court to take the case, warning that a patchwork of conflicting state labeling mandates would impose massive compliance costs and confuse consumers. The American Farm Bureau Federation argued that farmers depend on consistent federal labeling standards to make informed decisions about crop-protection products.
On the other side, consumer-advocacy organizations and a coalition of state attorneys general urged the Court to leave the Ninth Circuit's decision intact. They argued that FIFRA's savings clause preserves broad state authority and that Prop 65 serves a legitimate public-health function by filling gaps in federal disclosure.
The justices' willingness to step into this fight fits a broader pattern. The Court has taken up several cases this term that test the reach of federal regulatory authority and the interplay between state and federal power. That dynamic has played out in environmental litigation involving corporate liability and in challenges to state-level mandates affecting religious institutions and individual rights.
For conservatives, the case raises familiar concerns about regulatory overreach and scientific integrity. If a single state can override a federal agency's scientific finding and compel a warning the agency rejected, the practical effect is to let the most aggressive state regulator set the national standard. Companies selling products in all 50 states would face pressure to adopt the most restrictive label rather than maintain separate packaging for California.
That dynamic has long frustrated manufacturers and agricultural producers who view Prop 65 as a litigation-generation machine rather than a genuine public-health tool. The law's private-enforcement provision allows any individual or organization to sue a company for failing to provide a Prop 65 warning, creating a cottage industry of bounty-hunter lawsuits.
Bayer's brief highlighted this concern directly. The company noted that Prop 65 litigation has generated hundreds of millions of dollars in settlements, with a substantial share flowing to plaintiffs' attorneys rather than to consumers or public-health programs.
The justices will need to resolve several interlocking questions. First, does FIFRA's preemption clause reach state laws of general applicability like Prop 65, or only laws that specifically target pesticide labels? Second, does a conflict exist when a state requires a cancer warning that the EPA's own risk assessment does not support? Third, how much weight should courts give to the EPA's affirmative finding that glyphosate is not likely carcinogenic?
The Court's 2005 decision in Bates v. Dow Agrosciences will loom large. In that case, the justices held that FIFRA does not preempt all state-law claims related to pesticide labeling but does preempt state requirements that would force changes to EPA-approved labels. Both sides claim Bates supports their position, a split that helps explain why the Court granted cert.
Oral arguments have not yet been scheduled. The case will likely be argued in the fall, with a decision expected by the end of the term in June. As the Court's composition and direction continue to draw national attention, this case could produce one of the term's most consequential rulings for American agriculture, consumer law, and the federal regulatory framework.
The scientific disagreement at the heart of this case has never been fully resolved in the public square. IARC's 2015 classification evaluated glyphosate as a "hazard," asking whether the chemical is capable of causing cancer under any circumstances. The EPA's review evaluated "risk," asking whether glyphosate causes cancer at the exposure levels humans actually encounter. Those are fundamentally different questions, and they produced fundamentally different answers.
Critics of the IARC classification have pointed out that the agency used the same Group 2A category for red meat and for working as a hairdresser. Supporters counter that IARC's process is rigorous and independent of industry influence. The EPA, for its part, found that its own epidemiological and toxicological data did not support a cancer link at real-world exposure levels.
This scientific split is not merely academic. It has driven billions of dollars in litigation, shaped state regulatory policy, and now brought a major preemption question to the nation's highest court. The justices are not being asked to resolve the science. They are being asked to decide who gets to put a warning label on your weedkiller, and what happens when the state and federal answers collide.
The Court's growing docket of cases testing federal regulatory boundaries suggests the justices are ready to draw clearer lines. For farmers, manufacturers, and consumers caught between conflicting government mandates, those lines cannot come soon enough.
When one state can override a federal scientific finding and force a cancer warning the EPA itself rejected, the question stops being about herbicide. It becomes about who actually runs the regulatory system.
